Edoardo Francini

1.9k total citations
73 papers, 1.2k citations indexed

About

Edoardo Francini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Edoardo Francini has authored 73 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 24 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Edoardo Francini's work include Prostate Cancer Treatment and Research (33 papers), Radiopharmaceutical Chemistry and Applications (23 papers) and Colorectal Cancer Treatments and Studies (14 papers). Edoardo Francini is often cited by papers focused on Prostate Cancer Treatment and Research (33 papers), Radiopharmaceutical Chemistry and Applications (23 papers) and Colorectal Cancer Treatments and Studies (14 papers). Edoardo Francini collaborates with scholars based in Italy, United States and France. Edoardo Francini's co-authors include Roberto Petrioli, Guido Francini, Anna Ida Fiaschi, Giandomenico Roviello, Christopher J. Sweeney, Letizia Laera, Mary‐Ellen Taplin, Grace Shaw, Kathryn P. Gray and Philip W. Kantoff and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Edoardo Francini

73 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edoardo Francini Italy	20	632	554	291	215	210	73	1.2k
Deborah Bradley United States	19	792 1.3×	378 0.7×	287 1.0×	169 0.8×	502 2.4×	34	1.7k
Adrian Langleben Canada	17	416 0.7×	725 1.3×	158 0.5×	72 0.3×	316 1.5×	55	1.1k
Georg Stüben Germany	20	624 1.0×	488 0.9×	147 0.5×	155 0.7×	193 0.9×	46	1.2k
Dongmei Ji China	15	463 0.7×	539 1.0×	130 0.4×	126 0.6×	392 1.9×	92	1.2k
V. Damiano Italy	15	568 0.9×	796 1.4×	181 0.6×	128 0.6×	502 2.4×	34	1.3k
Deepak Kilari United States	18	466 0.7×	558 1.0×	281 1.0×	57 0.3×	300 1.4×	110	1.1k
Tatsunori Shimoi Japan	16	422 0.7×	775 1.4×	176 0.6×	243 1.1×	229 1.1×	105	1.2k
Ernesto Wasserman United States	17	358 0.6×	812 1.5×	377 1.3×	135 0.6×	418 2.0×	35	1.2k
Guoqing Liao China	18	502 0.8×	316 0.6×	237 0.8×	130 0.6×	511 2.4×	56	1.2k
Eijiro Nakamura Japan	19	472 0.7×	574 1.0×	241 0.8×	61 0.3×	512 2.4×	59	1.4k

Countries citing papers authored by Edoardo Francini

Since Specialization

Citations

This map shows the geographic impact of Edoardo Francini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edoardo Francini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edoardo Francini more than expected).

Fields of papers citing papers by Edoardo Francini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edoardo Francini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edoardo Francini. The network helps show where Edoardo Francini may publish in the future.

Co-authorship network of co-authors of Edoardo Francini

This figure shows the co-authorship network connecting the top 25 collaborators of Edoardo Francini. A scholar is included among the top collaborators of Edoardo Francini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edoardo Francini. Edoardo Francini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Francini, Edoardo, Neeraj Agarwal, Elena Castro, et al.. (2024). Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. European Urology. 87(1). 29–46. 9 indexed citations

Saieva, Calogero, Richard M. Lee‐Ying, Pier Vitale Nuzzo, et al.. (2023). Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.. Journal of Clinical Oncology. 41(6_suppl). 166–166. 1 indexed citations

Petrioli, Roberto, et al.. (2018). Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy. Clinical Colorectal Cancer. 17(4). 307–312. 22 indexed citations

Francini, Edoardo, Steven Yip, Haocheng Li, et al.. (2017). Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer. 16(2). 130–134. 16 indexed citations

Francini, Edoardo, Steven Yip, Neesar Ahmed, et al.. (2017). Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry. Annals of Oncology. 28. v278–v279. 3 indexed citations

Petrioli, Roberto, Giandomenico Roviello, Laura Zanotti, et al.. (2016). Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 102. 82–88. 28 indexed citations

Francini, Edoardo & Christopher J. Sweeney. (2016). Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer. European Urology. 70(3). 410–412. 32 indexed citations

Petrioli, Roberto, et al.. (2015). Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer.. PubMed. 35(5). 3097–102. 6 indexed citations

Petrioli, Roberto, Giandomenico Roviello, Anna Ida Fiaschi, et al.. (2015). Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 13(5). 441–446. 6 indexed citations

10.

Petrioli, Roberto, Giandomenico Roviello, Anna Ida Fiaschi, et al.. (2015). Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer. Anti-Cancer Drugs. 26(8). 878–883. 1 indexed citations

11.

Petrioli, Roberto, Edoardo Francini, Anna Ida Fiaschi, Letizia Laera, & Giandomenico Roviello. (2015). Targeted Therapies for Prostate Cancer. Cancer Investigation. 33(7). 276–285. 6 indexed citations

12.

Roviello, Giandomenico, Edoardo Francini, Letizia Laera, et al.. (2015). Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. Cancer Biology & Therapy. 16(4). 493–497. 2 indexed citations

13.

Petrioli, Roberto, Giandomenico Roviello, Anna Ida Fiaschi, et al.. (2015). Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. Anti-Cancer Drugs. 26(6). 682–686. 4 indexed citations

14.

Francini, Edoardo, Anna Ida Fiaschi, Roberto Petrioli, et al.. (2015). Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate. Anti-Cancer Drugs. 26(8). 884–887. 3 indexed citations

15.

Petrioli, Roberto, Edoardo Francini, Anna Ida Fiaschi, et al.. (2015). Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study. Medical Oncology. 32(4). 134–134. 11 indexed citations

16.

Francini, Edoardo, Roberto Petrioli, Anna Ida Fiaschi, Letizia Laera, & Giandomenico Roviello. (2014). Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer. Medicine. 93(27). e163–e163. 1 indexed citations

17.

Petrioli, Roberto, Antonella Licchetta, Giandomenico Roviello, et al.. (2012). CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab. Cancer Investigation. 30(1). 65–71. 27 indexed citations

18.

Francini, Edoardo, et al.. (2011). Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. The Journal of the American Dental Association. 142(5). 506–513. 23 indexed citations

19.

Licchetta, Antonella, Pierpaolo Correale, Cristina Migali, et al.. (2010). Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate. Journal of Chemotherapy. 22(3). 201–204. 23 indexed citations

20.

Francini, Guido, Roberto Petrioli, A Montagnani, et al.. (2006). Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. British Journal of Cancer. 95(2). 153–158. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact